No Data
No Data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
Jefferies Downgrades Astellas Pharma (ALPMF) to a Hold
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
List of sell conversion stocks in the market. Code Company name Closing price SAR Tokyo Prime <1375> Yukiguni Maitake 1002 1028 <1605> INPEX 2420 2508 <167A> Ryosan Hiso Yo 3050 3145 <1805> Tobishima Corporation 1533 1580 <1820> Nishimatsu Construction
Stocks that moved the previous day Part 2: Libertas, SIG Group, Wolves etc.
Stock Name <Code>, Closing Price on the 19th⇒ Compared to the Previous Day, M&A Soken <9552> 3730 -165. On the 19th, there was a headwind for small and medium-sized growth stocks. Astellas Pharma <4503> 1642 -55. Investment rating was downgraded by Jefferies Securities. Tohoku Electric Power <9506> 1350.5 -44. On the 18th, there was a strong movement of funds shifted to electric utilities stocks. However, Tokyo Electric Power HD <9501> 796.6 -24.3. The electric utilities stocks, which rose on the 18th, reversed to a complete drop. JVC Kenwood <6632> 90.
Jefferies Downgrades Astellas Pharma to Hold From Buy, Adjusts Price Target to 1,700 Yen From 2,100 Yen
05:50 AM EDT, 07/19/2024 (MT Newswires) -- Jefferies Downgrades Astellas Pharma to Hold From Buy, Adjusts Price Target to 1,700 Yen From 2,100 YenPrice (JPY): $1642.00, Change: $-55.00, Percent
Bronco B, SE H&I, Good Product Plan, etc.
<4503> Astellas Pharma fell sharply by 55 to 1642. Jefferies Securities downgraded its investment rating from "buy" to "hold" and lowered its target stock price from 2100 yen to 1700 yen. Sales forecasts for overactive bladder treatment Mirabegron, hot flush treatment Veoza, and geographic atrophy treatment Izervay have been downwardly revised, and annual revenue estimates for the next five years are expected to decrease by an average of 5%. The EBITDA estimate appears to be about 9% below consensus. <7